GHK-Cu is a copper-bound peptide whose blood levels fall with age. Strongest human evidence is skin: firmer texture and faster ulcer healing in small studies, with mild local side effects. Injectable longevity use is mostly mechanism and clinic anecdote. Dominant risks are product quality and unknown long-term safety. Medium support for skin; speculative for whole-body claims. (Full Review)

Protocol

Topical cosmetic (best-studied route)

~0.05–1% once or twice daily

Leave-on serums or creams on clean dry skin; many trials used twice-daily for 8–12 weeks

Injectable (experimental / clinic use)

~1–2 mg daily or several times weekly

Compounded subcutaneous; no consensus pharmaceutical dose or approved systemic indication for longevity

Wound-care topical

~0.4–2% gels/dressings

Medical gels/dressings under clinician wound protocols; not a self-care substitute for infection control and offloading

Time to effect

Cosmetic Skin

4–12 weeks

Firmness, density, and fine-line changes typically assessed over this window

Wound Healing

Weeks

Closure and area trends measured over weeks under clinical wound protocols

Systemic Longevity

Not validated

Subjective whole-body effects lack validated timelines in human data

Benefits

Medium: Improved facial skin firmness, density, and fine lines; accelerated cutaneous wound healing

Low: Support for hair follicle environment and density

Speculative: Collagen IV and dermal–epidermal junction support; systemic regenerative and longevity gene-expression effects; neuroprotection and cognitive resilience; lung protection and anti-fibrotic effects

Contraindications

Wilson disease or known copper toxicosis (systemic use)

Known allergy to GHK-Cu or formulation excipients

Pregnancy and lactation (insufficient safety data; avoid non-essential systemic use)

Active skin infection at intended topical site until controlled

Reliance on untested research-chemical injectables without identity/purity verification

Key Interactions

Strong acids / high-dose L-ascorbic acid (vitamin C) topicals

Potent retinoids (tretinoin, adapalene) and chemical peels

Copper supplements and multivitamins with high copper (if injectable)

Chelators used for copper overload (e.g., penicillamine, trientine)

Other regenerative peptides (BPC-157, TB-500)

Anticoagulants / antiplatelets (warfarin, apixaban, aspirin, clopidogrel) for injectables

Risk & Side Effects

Medium: Product quality and contamination risk

Low: Local irritation, stinging, injection-site reactions, or contact sensitivity; transient skin dullness or breakouts with overuse; transient blue-green discoloration of skin or fabrics

Speculative: Systemic copper excess with aggressive parenteral use; unknown long-term systemic safety of chronic injection

Monitoring

Marker	Target	Why
Serum copper	Lab-specific; often ~70–140 µg/dL	Detect excess or deficiency if systemic use
Ceruloplasmin	Lab reference (often ~20–40 mg/dL)	Copper transport protein; Wilson workup context
CBC	Age/sex-appropriate reference	General safety if injecting
CMP	Lab reference	Liver/kidney context for systemic protocols
hs-CRP	Often <1.0 mg/L functional goal	Nonspecific inflammation context
Wound area / photos	Improving trend vs own baseline	Primary efficacy for skin/wounds

Cadence: Cosmetics: reassess at 4, 8, and 12 weeks, then every 3–6 months if continued. Injectables: labs at 4–12 weeks, then every 6–12 months, plus ongoing product quality checks. Baseline copper history, photos, and (if injecting) serum copper, ceruloplasmin, CBC, and CMP before start.

Qualitative Assessment

Skin firmness and texture on touch
Makeup “settling”
Post-procedure recovery speed
Itch/redness burden
Hair shedding subjective count if used for scalp

GHK-Cu for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment